Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/20308656http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/20308656http://www.w3.org/2000/01/rdf-schema#comment"PURPOSE The purpose of this study was to investigate frequency and prognostic significance of high EVI1 expression in acute myeloid leukemia (AML). PATIENTS AND METHODS A diagnostic assay detecting multiple EVI1 splice variants was developed to determine the relative EVI1 expression by single real-time quantitative polymerase chain reaction in 1,382 newly diagnosed adult patients with AML younger than 60 years. Patients were treated on four Dutch-Belgian HOVON (n = 458) and two German-Austrian AML Study Group protocols (n = 924). Results The EVI1 assay was tested in the HOVON cohort and validated in the AMLSG cohort. High EVI1 levels (EVI1(+)) were found with similar frequencies in both cohorts combined, with a 10.7% incidence (148 of 1,382). EVI1(+) independently predicted low complete remission (CR) rate (odds ratio, 0.54; P = .002), adverse relapse-free survival (RFS; hazard ratio [HR], 1.32; P = .05), and event-free survival (EFS; HR, 1.46; P < .001). This adverse prognostic impact was more pronounced in the intermediate cytogenetic risk group (EFS; HR, 1.64; P < .001; and RFS; HR, 1.55; P = .02), and was also apparent in cytogenetically normal AML (EFS; HR, 1.67; P = .008). Besides inv(3)/t(3;3), EVI1(+) was significantly associated with chromosome abnormalities monosomy 7 and t(11q23), conferring prognostic impact within these two cytogenetic subsets. EVI1(+) was virtually absent in favorable-risk AML and AML with NPM1 mutations. Patients with EVI1(+) AML (n = 28) who received allogeneic stem cell transplantation in first CR had significantly better 5-year RFS (33% +/-10% v 0%). CONCLUSION EVI1 expression in AML is unequally distributed in cytogenetic subtypes. It predicts poor outcome, particularly among intermediate cytogenetic risk AML. Patients with EVI1(+) AML may benefit from allogeneic transplantation in first CR. Pretreatment EVI1 screening should be included in risk stratification."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.org/dc/terms/identifier"doi:10.1200/jco.2009.26.0646"xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Dohner K."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Schlegelberger B."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Delwel R."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Ossenkoppele G.J."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Lowenberg B."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Dohner H."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Valk P.J."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Ganser A."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Krauter J."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Kayser S."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Schlenk R.F."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Germing U."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Verdonck L.F."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Lubbert M."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Lugthart S."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Groschel S."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Eiwen K."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Goudswaard C."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"Schmidt-Wolf I."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/author"van Putten W.J."xsd:string
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/date"2010"xsd:gYear
http://purl.uniprot.org/citations/20308656http://purl.uniprot.org/core/name"J Clin Oncol"xsd:string
▶